@article{fdi:010078949,
  title = {{A}rchaea, specific genetic traits, and development of improved bacterial live biotherapeutic products : another face of next-generation probiotics},
  author = {{F}adhlaoui, {K}. and {A}rnal, {M}. {E}. and {M}artineau, {M}. and {C}amponova, {P}. and {O}llivier, {B}ernard and {O}'{T}oole, {P}. {W}. and {B}rugere, {J}. {F}.},
  editor = {},
  language = {{ENG}},
  abstract = {{T}rimethylamine ({TMA}) and its oxide {TMAO} are important biomolecules involved in disease-associated processes in humans (e.g., trimethylaminuria and cardiovascular diseases). {TMAO} in plasma (p{TMAO}) stems from intestinal {TMA}, which is formed from various components of the diet in a complex interplay between diet, gut microbiota, and the human host. {M}ost approaches to prevent the occurrence of such deleterious molecules focus on actions to interfere with gut microbiota metabolism to limit the synthesis of {TMA}. {S}ome human gut archaea however use {TMA} as terminal electron acceptor for producing methane, thus indicating that intestinal {TMA} does not accumulate in some human subjects. {T}herefore, a rational alternative approach is to eliminate neo-synthesized intestinal {TMA}. {T}his can be achieved through bioremediation of {TMA} by these peculiar methanogenic archaea, either by stimulating or providing them, leading to a novel kind of next-generation probiotics referred to as archaebiotics. {F}inally, specific components which are involved in this archaeal metabolism could also be used as intestinal {TMA} sequesters, facilitating {TMA} excretion along with stool. {R}eferring to a standard pharmacological approach, these {TMA} traps could be synthesized ex vivo and then delivered into the human gut. {A}nother approach is the engineering of known probiotic strain in order to metabolize {TMA}, i.e., live engineered biotherapeutic products. {T}hese alternatives would require, however, to take into account the necessity of synthesizing the 22nd amino acid pyrrolysine, i.e., some specificities of the genetics of {TMA}-consuming archaea. {H}ere, we present an overview of these different strategies and recent advances in the field that will sustain such biotechnological developments.},
  keywords = {{T}rimethylamine oxide {TMAO} ; {C}ardiovascular disease {CVD} ; {A}rchaebiotics ; {T}rimethylamine {TMA} ; {T}rimethylaminuria {TMAU} ; {L}ive biotherapeutic products ; {LBP}},
  booktitle = {},
  journal = {{A}pplied {M}icrobiology and {B}iotechnology},
  volume = {104},
  numero = {11},
  pages = {4705--4716},
  ISSN = {0175-7598},
  year = {2020},
  DOI = {10.1007/s00253-020-10599-8},
  URL = {https://www.documentation.ird.fr/hor/fdi:010078949},
}